Emmanuelle Clerisme-Beaty

Jun 27, 2024 | bmjopenrespres.bmj.com | Kevin Flaherty |Kevin Brown |Athol U Wells |Emmanuelle Clerisme-Beaty

The PF-ILD trial (1199.247, NCT02999178) is a multicentre, prospective, randomised, double-blind, placebo-controlled study to investigate the efficacy and safety of nintedanib in patients with progressive fibrosing lung disease over 52 weeks. The study is conducted at specialised referral centres experienced in ILD management in approximately 15 countries of the Americas, Europe and Asia.